Abstract: Presented herein are powder formulations comprising dihydroergotamine (DHE), or a pharmaceutically acceptable salt thereof. In addition to such formulations, also presented herein are methods comprising intranasally administering powder formulations comprising dihydroergotamine, or a pharmaceutically acceptable salt thereof. The presented methods can be used for treating headache, for example, for rapid onset treatment of headache, including migraine, e.g. acute treatment of migraine with or without aura.

Abstract: Disclosed herein are pharmaceutical powder compositions, methods of making such compositions, and uses thereof.

Abstract: The present disclosure provides devices for delivery of powder formulations and methods of manufacture and use of such devices.

Abstract: The present disclosure provides devices for delivery of powder formulations and methods of manufacture and use of such devices.

Abstract: A nozzled cartridge (20) for storing medicine, according to an aspect of the present application, includes a medicine container (21) that is to be filled with a predetermined quantity of a powdered medicine, a nozzle portion (22) that is formed on the medicine container (21) and that ejects the powdered medicine, a closing member (24) that closes an opening (22a) in the nozzle portion (22), and a valve member (25) that functions as a plug to close another opening (23a) in the medicine container (21), and that is opened when administering medicine. The nozzled cartridge (20) is detachably mountable to a sprayer (30) when administering medicine.

Abstract: Presented herein are powder formulations comprising dihydroergotamine (DHE), or a pharmaceutically acceptable salt thereof. In addition to such formulations, also presented herein are methods comprising intranasally administering powder formulations comprising dihydroergotamine, or a pharmaceutically acceptable salt thereof. The presented methods can be used for treating headache, for example, for rapid onset treatment of headache, including migraine, e.g. acute treatment of migraine with or without aura.

Abstract: An object of the present invention is to provide a powder formulation for intranasal administration, which efficiently exhibits a medicinal effect, and the like. The object can be achieved by a powder formulation for intranasal administration comprising composite particles in which an active ingredient and a water-insoluble polysaccharide are cohered to each other.

Abstract: Provided herein are vaccine compositions for example in a dry powder form for intranasal delivery, and their preparation methods. Also provided are methods of using vaccine compositions, for example in stimulating mucosal or systemic immune responses by delivering the vaccine compositions intranasally.

Abstract: A device according to one aspect of the present invention is an intranasal powdered medicine dispensing device (10) for dispensing a predetermined dose of a powdered medicine into a nasal cavity. The device includes a nozzle member (20) that includes a filling space (22) for a powdered medicine (M) and an ejection opening (26) for the powdered medicine (M), a closing member that closes the ejection opening (26), a sealing member (40) that seals an opening (24) of the filling space (22), an injection pump member (50) that sends out air, as the injection pump member contracts, to eject the powdered medicine from the ejection opening (26), a puncturing member (60) that moves, as the injection pump member (50) contracts, and forms a hole by puncturing in the sealing member (40) while moving, and a guide member (70) that restricts the puncturing member (60) from moving in a direction perpendicular to the direction of the movement thereof.

Abstract: An object of the present invention is to provide a powder preparation and the like suitable for selective administration to an olfactory region and the like. The object is achieved by a powder preparation for selectively administering an active ingredient to an olfactory region in a nasal cavity, the powder preparation comprising the active ingredient and having a bulk density of 0.1 to 0.5 g/cm3 and a Hausner ratio of 1.6 to 2.4.

Abstract: Disclosed herein are pharmaceutical powder compositions, methods of making such compositions, and uses thereof.

Abstract: Disclosed herein are pharmaceutical powder compositions, methods of making such compositions, and uses thereof.

Abstract: A nozzled cartridge (20) for storing medicine, according to an aspect of the present application, includes a medicine container (21) that is to be filled with a predetermined quantity of a powdered medicine, a nozzle portion (22) that is formed on the medicine container (21) and that ejects the powdered medicine, a closing member (24) that closes an opening (22a) in the nozzle portion (22), and a valve member (25) that functions as a plug to close another opening (23a) in the medicine container (21), and that is opened when administering medicine. The nozzled cartridge (20) is detachably mountable to a sprayer (30) when administering medicine.

Abstract: Presented herein are powder formulations comprising dihydroergotamine (DHE), or a pharmaceutically acceptable salt thereof. In addition to such formulations, also presented herein are methods comprising intranasally administering powder formulations comprising dihydroergotamine, or a pharmaceutically acceptable salt thereof. The presented methods can be used for treating headache, for example, for rapid onset treatment of headache, including migraine, e.g. acute treatment of migraine with or without aura.

Abstract: Provided herein are methods for generating dry vaccine powder formulations. Dry vaccine powder formulations can be used for intranasal delivery. Also provided are methods for stimulating local mucosal and systemic immunity by intranasal vaccine delivery.

Abstract: Presented herein are powder formulations comprising dihydroergotamine (DHE), or a pharmaceutically acceptable salt thereof. In addition to such formulations, also presented herein are methods comprising intranasally administering powder formulations comprising dihydroergotamine, or a pharmaceutically acceptable salt thereof. The presented methods can be used for treating headache, for example, for rapid onset treatment of headache, including migraine, e.g. acute treatment of migraine with or without aura.

Abstract: [Subject] A test substance application system for animal experiment capable of administering a required amount of a test substance uniformly and reliably from a nose or a mouth into a nasal cavity or into a lung of an experimental animal is provided. [Means for Solution] The system includes a respiration monitoring device 2 that monitors a respiration state of an experimental animal detected by a respiration pick-up device 1 to thereby measure a timing upon switching from an expiratory phase to an inhalatory phase and outputs a trigger signal T at that timing, and an application device 3 that sprays a predetermined amount of a test substance into a nasal cavity or an oral cavity of the experimental animal when the trigger signal T is outputted from the device 2.

Abstract: The present disclosure provides devices for delivery of powder formulations and methods of manufacture and use of such devices.

Abstract: Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties, and physiologically active substance.

Abstract: Provided herein are vaccine compositions for example in a dry powder form for intranasal delivery, and their preparation methods. Also provided are methods of using vaccine compositions, for example in stimulating mucosal or systemic immune responses by delivering the vaccine compositions intranasally.